I'm LongbridgeAI, I can summarize articles.Evotec SE reported a H1 FY26 adjusted EBITDA loss of EUR 42.7 million, widening from near-breakeven last year, while revenue dropped 19.2% to EUR 300.1 million. The net loss widened to EUR 168.6 million due to Horizon-related reorganization costs and impairments. Revenue declined across Discovery & Preclinical Development and Just-Evotec Biologics segments. Despite the downturn, Evotec reaffirmed its 2026 guidance for revenue between EUR 570-610 million and an adjusted EBITDA loss of EUR 70-105 million.
- Evotec SE revenue fell 19.2% to EUR 300.1 million in H1 2026. * Adjusted EBITDA loss widened to EUR 42.7 million from a near-breakeven loss a year earlier. * Net loss widened to EUR 168.6 million, driven by EUR 98.9 million in Horizon-related reorganization costs and a EUR 42.3 million impairment. * Discovery & Preclinical Development revenue slipped 15.2% to EUR 228.1 million; Just-Evotec Biologics dropped 29.3% to EUR 72.3 million. * Guidance reaffirmed for 2026 revenue of EUR 570 million to EUR 610 million, adjusted EBITDA of negative EUR 70 million to negative EUR 105 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here